{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:41:00Z","timestamp":1788212460458,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T00:00:00Z","timestamp":1500249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T00:00:00Z","timestamp":1500249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1038\/bmt.2017.157","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T13:40:35Z","timestamp":1500298835000},"page":"1526-1529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Impact of molecular residual disease post allografting in myelofibrosis patients"],"prefix":"10.1038","volume":"52","author":[{"given":"C","family":"Wolschke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Badbaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Zabelina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Christopeit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Triviai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Zander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Alchalby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Fehse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,17]]},"reference":[{"key":"BFbmt2017157_CR1","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","volume":"114","author":"N Kr\u00f6ger","year":"2009","unstructured":"Kr\u00f6ger N, Holler E, Kobbe G, Bornh\u00e4user M, Schwerdtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264\u20135270.","journal-title":"Blood"},{"key":"BFbmt2017157_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","volume":"20","author":"V Gupta","year":"2014","unstructured":"Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2014; 20: 89\u201397.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2017157_CR3","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","volume":"119","author":"BL Scott","year":"2012","unstructured":"Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 2012; 119: 2657\u20132664.","journal-title":"Blood"},{"key":"BFbmt2017157_CR4","first-page":"2831","volume":"93","author":"P Guardiola","year":"1999","unstructured":"Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arcese W et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood 1999; 93: 2831\u20132838.","journal-title":"Blood"},{"key":"BFbmt2017157_CR5","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2014-04-572545","volume":"124","author":"D Rondelli","year":"2014","unstructured":"Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood 2014; 124: 1183\u20131191.","journal-title":"Blood"},{"key":"BFbmt2017157_CR6","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1182\/blood-2008-11-190975","volume":"113","author":"N Kr\u00f6ger","year":"2009","unstructured":"Kr\u00f6ger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuk F et al. JAK2V617F-triggered preemptive and salvage adoptive immunotherapy with donor lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 2009; 113: 1866\u20131868.","journal-title":"Blood"},{"key":"BFbmt2017157_CR7","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lagout C et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005; 434: 1144\u20131148.","journal-title":"Nature"},{"key":"BFbmt2017157_CR8","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.","journal-title":"PLoS Med"},{"key":"BFbmt2017157_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice Fl, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with unmutated JAK2. N Engl J Med 2013; 369: 2391\u20132405.","journal-title":"N Engl J Med"},{"key":"BFbmt2017157_CR10","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379\u20132390.","journal-title":"N Engl J Med"},{"key":"BFbmt2017157_CR11","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1182\/blood-2006-08-039909","volume":"109","author":"N Kr\u00f6ger","year":"2007","unstructured":"Kr\u00f6ger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornh\u00e4user M et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007; 109: 1316\u20131321.","journal-title":"Blood"},{"key":"BFbmt2017157_CR12","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","volume":"116","author":"H Alchalby","year":"2010","unstructured":"Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010; 116: 3572\u20133581.","journal-title":"Blood"},{"key":"BFbmt2017157_CR13","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/bmt.2016.14","volume":"51","author":"A Badbaran","year":"2016","unstructured":"Badbaran A, Fehse B, Christopeit M, Aranyossy T, Ayuk FA, Wolschke C et al. Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patents with myelofibrosis following allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51: 872\u2013873.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2017157_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/bjh.12013","volume":"159","author":"E Klyuchnikov","year":"2012","unstructured":"Klyuchnikov E, Holler E, Bornh\u00e4user M, Kobbe G, Nagler A, Shimoni A et al. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Br J Haematol 2012; 159: 172\u2013181.","journal-title":"Br J Haematol"},{"key":"BFbmt2017157_CR15","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1515\/cclm-2013-0768","volume":"52","author":"K Haslam","year":"2014","unstructured":"Haslam K, Molloy KM, Conneally E, Langabeer SE . Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms. Clin Chem Lab Med 2014; 52: e29\u2013e31.","journal-title":"Clin Chem Lab Med"},{"key":"BFbmt2017157_CR16","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3324\/haematol.2012.076901","volume":"98","author":"T Lange","year":"2013","unstructured":"Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, J\u00e4kel N et al. JAK2 p. V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica 2013; 98: 722\u2013728.","journal-title":"Haematologica"},{"key":"BFbmt2017157_CR17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/bjh.12904","volume":"166","author":"K Haslam","year":"2014","unstructured":"Haslam K, Langabeer SE, Molloy K, McMullin MF, Conneally E . Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation. Br J Haematol 2014; 166: 800\u2013802.","journal-title":"Br J Haematol"},{"key":"BFbmt2017157_CR18","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/bmt.2009.367","volume":"45","author":"H Alchalby","year":"2010","unstructured":"Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander AR et al. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Bone Marrow Transplant 2010; 45: 1404\u20131407.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2017157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2017157","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bmt.2017.157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2017157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:20:18Z","timestamp":1648063218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2017157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,17]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["BFbmt2017157"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2017.157","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,17]]},"assertion":[{"value":"3 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}